Document Detail


Optimal treatment with telaprevir for chronic HCV infection.
MedLine Citation:
PMID:  23286840     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Telaprevir is a recently approved direct-acting antiviral against hepatitis C virus (HCV) that works through inhibition of the NS3/4A serine protease inhibitor.Phase 2b and 3 studies have shown marked increase in sustained virological response rates in both treatment- naïve and treatment-experienced patients with HCV genotype 1 treated with a telaprevir-containing regimen compared with pegylated interferon (PEG-IFN) and ribavirin alone. The most commonly observed side effects of telaprevir therapy are anaemia to a greater degree than that observed with PEG-IFN/ribavirin alone; eczematous rash, which can be severe in a minority of patients; and anorectal discomfort.
Authors:
Arun B Jesudian; Ira M Jacobson
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3-13     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Inc.
Affiliation:
Division of Gastroenterology and Hepatology, Center for Study of Hepatitis C, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In-Situ Crystallization Route to Nanorod-Aggregated Functional ZSM-5 Microspheres.
Next Document:  Optimal treatment with boceprevir for chronic HCV infection.